Generic name: FLUOCINOLONE ACETONIDE 0.59mg
Dosage form: intravitreal implant
Medically reviewed on December 20, 2017.
RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg is implanted into the posterior segment of the affected eye through a pars plana incision.
The implant contains one tablet of 0.59 mg of fluocinolone acetonide. RETISERT is designed to release fluocinolone acetonide at a nominal initial rate of 0.6 mcg/day, decreasing over the first month to a steady state between 0.3-0.4 mcg/day over approximately 30 months. Following depletion of fluocinolone acetonide as evidenced by recurrence of uveitis, RETISERT may be replaced.
Handling of Implant
Caution should be exercised in handling RETISERT in order to avoid damage to the implant, which may result in an increased rate of drug release from the implant. Thus, RETISERT should be handled only by the suture tab. Care should be taken during implantation and explantation to avoid sheer forces on the implant that could disengage the silicone cup reservoir (which contains a fluocinolone acetonide tablet) from the suture tab. Aseptic technique should be maintained at all times prior to and during the surgical implantation procedure.
RETISERT should not be resterilized by any method.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Retisert (fluocinolone ophthalmic)
- Retisert Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- Pricing & Coupons
- En Español
- 4 Reviews
- Drug class: ophthalmic steroids